Near-term strategies for biotech drug developers facing shifting healthcare dynamics

A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.

Read the full article

1f19cd397a348ae134fbb8b153b1f4f6.jpg

Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”

Watch the full video

The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.

Return to Insights Center

Related Insights

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Webinar

Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Jan 7, 2025

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Related Insights

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Show more